MRUS Merus NV

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRUS

Price (delayed)

$47.5

Market cap

$2.75B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3

Enterprise value

$2.56B

Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed ...

Highlights
MRUS's debt is down by 10% year-on-year
Merus's equity has increased by 44% YoY but it has decreased by 9% from the previous quarter
Merus's quick ratio has increased by 38% YoY but it has decreased by 15% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.merus.nl
Peers: OMER OMGA

Key stats

What are the main financial stats of MRUS
Market
Shares outstanding
57.88M
Market cap
$2.75B
Enterprise value
$2.56B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.7
Price to sales (P/S)
55.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
58.19
Earnings
Revenue
$43.95M
EBIT
-$166.26M
EBITDA
-$163.72M
Free cash flow
-$146.19M
Per share
EPS
-$3
Free cash flow per share
-$2.83
Book value per share
$6.17
Revenue per share
$0.85
TBVPS
$8.79
Balance sheet
Total assets
$455.49M
Total liabilities
$99.15M
Debt
$12.16M
Equity
$356.34M
Working capital
$299.73M
Liquidity
Debt to equity
0.03
Current ratio
5.34
Quick ratio
5.16
Net debt/EBITDA
1.17
Margins
EBITDA margin
-372.5%
Gross margin
100%
Net margin
-352.6%
Operating margin
-356.2%
Efficiency
Return on assets
-37.6%
Return on equity
-50.6%
Return on invested capital
-86.5%
Return on capital employed
-43%
Return on sales
-378.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRUS stock price

How has the Merus stock price performed over time
Intraday
1.02%
1 week
5.72%
1 month
5.09%
1 year
157.31%
YTD
72.73%
QTD
5.49%

Financial performance

How have Merus's revenue and profit performed over time
Revenue
$43.95M
Gross profit
$43.95M
Operating income
-$156.55M
Net income
-$154.94M
Gross margin
100%
Net margin
-352.6%
Merus's net income has decreased by 18% YoY but it has increased by 12% from the previous quarter
MRUS's net margin is down by 12% year-on-year but it is up by 9% since the previous quarter
The operating margin has grown by 7% YoY
Merus's gross profit has increased by 6% YoY but it has decreased by 3.8% QoQ

Growth

What is Merus's growth rate over time

Valuation

What is Merus stock price valuation
P/E
N/A
P/B
7.7
P/S
55.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
58.19
The EPS has grown by 20% from the previous quarter but it has contracted by 2.7% YoY
The P/B is 103% more than the 5-year quarterly average of 3.8 and 93% more than the last 4 quarters average of 4.0
Merus's equity has increased by 44% YoY but it has decreased by 9% from the previous quarter
The P/S is 189% higher than the 5-year quarterly average of 19.3 and 102% higher than the last 4 quarters average of 27.6
The revenue is up by 6% year-on-year but it has declined by 3.8% since the previous quarter

Efficiency

How efficient is Merus business performance
The ROE has grown by 20% from the previous quarter but it has contracted by 13% YoY
The ROA has declined by 19% year-on-year but it is up by 16% since the previous quarter
The ROS has contracted by 18% YoY but it has grown by 3.4% from the previous quarter
The ROIC has grown by 11% from the previous quarter but it has contracted by 10% YoY

Dividends

What is MRUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRUS.

Financial health

How did Merus financials performed over time
Merus's quick ratio has increased by 38% YoY but it has decreased by 15% QoQ
The current ratio rose by 38% year-on-year but it has declined by 15% since the previous quarter
MRUS's debt is 97% smaller than its equity
Merus's equity has increased by 44% YoY but it has decreased by 9% from the previous quarter
MRUS's debt to equity is down by 40% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.